Melanoma Is No Longer "Just a Skin Cancer" —
It's Four Diseases.
Cutaneous, acral, mucosal, and uveal melanoma have completely different biology — and completely different treatment paths. Today's decisions depend on BRAF/KIT status, TIL grade, HLA type, and disease stage: from neoadjuvant immunotherapy that can eliminate stage III disease before surgery, to FDA-approved TIL therapy after PD-1 failure, to mRNA vaccines that train your immune system against recurrence.
💡 The Reality Check: Myth: "Melanoma is curable with surgery, and immunotherapy works for everyone." Reality: Modern melanoma care has been rewritten. Stage III disease is increasingly treated before surgery with neoadjuvant nivolumab+ipilimumab (NADINA), combination immunotherapy now shows over 50% survival at 10 years in advanced disease (CheckMate-067), and patients who fail PD-1 now have an FDA-approved TIL therapy (lifileucel, 2024). But acral, mucosal, and uveal melanoma are biologically distinct — they rarely respond like cutaneous melanoma and need dedicated pathways (KIT inhibitors, tebentafep, liver-directed therapy).
Biomarker Map: 10 Markers That Drive Melanoma Decisions
Melanoma is defined by its biology. These 10 biomarkers determine treatment selection and prognosis.
BRAF V600E/K
~40-50% cutaneousDetermines targeted therapy vs. IO-first. BRAF+ patients can receive dabrafenib+trametinib or IO-first depending on disease urgency.
KIT Mutations
~10-15% acral/mucosalImatinib/nilotinib if positive. KIT testing is mandatory for acral and mucosal melanoma before starting IO.
TIL Grade / TMB
VariableHigh TIL + high TMB = better IO response. UV signature correlates with higher TMB and better outcomes.
LDH
Prognostic stage IVPrognostic marker in stage IV. Enters AJCC staging. Elevated LDH predicts poorer prognosis and may alter treatment intensity.
HLA-A*02:01
Required for tebentafepNecessary for tebentafep in uveal melanoma. Must be tested before considering this therapy.
GNAQ / GNA11
Uveal driversDriver mutations in uveal melanoma. Differentiate uveal from cutaneous biology — GNAQ/GNA11 tumors respond differently to IO.
B2M / JAK1/2
Resistance mechanismLoss of IFN-γ pathway — key mechanism of IO resistance. Re-biopsy at progression should test B2M/JAK status.
SF3B1
Uveal prognosticPrognostic marker in uveal melanoma. Identifies patients with worse outcomes and need for more aggressive monitoring.
Sentinel Node Status
Stage III decisionDetermines need for neoadjuvant therapy. Positive sentinel node indicates stage III and should trigger consideration of neoadjuvant nivo+ipi.
PD-L1
Limited utilityLimited clinical utility. PD-L1 alone is not decision-making in melanoma — unlike NSCLC, it doesn't predict IO response reliably.
Resistance Matrix: Melanoma
Understanding resistance mechanisms guides next-line therapy selection.
| Disease | Failed Treatment | Why It Failed | Test Now | Next Option | Best Country |
|---|---|---|---|---|---|
| Cutaneous (BRAF-WT) | PD-1 monotherapy | T-cell exhaustion, low TMB | TIL grade, TMB, B2M/JAK | Lifileucel (TIL) or nivo+ipi | 🇺🇸 USA / 🇨🇳 China |
| Cutaneous (BRAF+) | PD-1 | BRAF-driven escape | BRAF V600 confirm | BRAF/MEK (dabrafenib+trametinib) | 🇩🇪 Germany / 🇺🇸 USA |
| Cutaneous | Nivo+Ipi | Exhaustion / B2M loss | B2M, JAK1/2, HLA | TIL therapy / mRNA vaccine trial | 🇺🇸 USA / 🇨🇳 China |
| Uveal | PD-1 | GNAQ/GNA11 biology, low TMB | HLA-A*02:01, GNAQ/GNA11 | Tebentafep + liver-directed | 🇺🇸 USA / 🇩🇪 Germany |
| Mucosal/Acral | PD-1 | Low TMB, non-UV biology | KIT, PD-L1 | KIT inhibitor + PD-1+axitinib | 🇨🇳 China |
| Brain Mets | Systemic IO | CNS sanctuary | Brain MRI | Nivo+Ipi + SRS | 🇺🇸 USA / 🇩🇪 Germany / 🇰🇷 Korea |
Critical Insight: Re-biopsy at progression is essential — biomarkers change under treatment pressure. B2M loss, JAK1/2 mutations, and BRAF resistance mechanisms guide next-line therapy selection.
Decision Trees: 3 Clinical Scenarios
Evidence-based decision pathways for the most common melanoma scenarios.
🌳 Tree 1 — Stage III Resectable
- Macroscopic stage III? → Neoadjuvant nivo+ipi (NADINA) → pathology response guides adjuvant
- Microscopic / sentinel+? → Upfront surgery + adjuvant (pembro/nivo or BRAF/MEK if mutated)
- Key Trial: NADINA (NEJM 2024) — established neoadjuvant IO as standard for stage III
🌳 Tree 2 — Stage IV First-Line
- BRAF V600+? → IO-first (nivo+ipi) unless rapid control needed → then BRAF/MEK
- BRAF-WT? → nivo+ipi (fit) / nivo+relatlimab / pembro mono (frail)
- Key Trial: CheckMate-067 — 10-year OS >50% with nivo+ipi
🌳 Tree 3 — Post-PD-1 Progression
- BRAF+? → BRAF/MEK
- BRAF-WT? → Lifileucel (TIL) — ECOG 0-1 required
- Uveal? → Tebentafep (HLA-A*02:01+)
- Key Approval: Lifileucel (Amtagvi) — FDA February 2024
Counter-Signal: When to Pause
Not every patient should pursue aggressive treatment. These scenarios require careful reconsideration.
ECOG ≥2
Lifileucel (TIL) tolerability is poor in ECOG ≥2 patients. Consider clinical trials or best supportive care.
Uveal Melanoma
Cutaneous IO pathways rarely work. Use tebentafep (HLA-A*02:01+) or liver-directed therapy.
Active Brain Mets Untreated
Treat CNS lesions first with SRS or surgery before initiating systemic therapy.
Autoimmune Contraindication
IO carries high risk in patients with active autoimmune disease. Alternative therapies (BRAF/MEK, TIL) may be safer.
CancerCareE position: We will tell you when aggressive treatment is not appropriate. Request a candid assessment →
Country Logic by Melanoma Subtype
Each country offers unique strengths for melanoma treatment — from TIL therapy to mucosal/acral expertise.
USA — TIL, Tebentafep & mRNA Vaccines
FDA-approved lifileucel (TIL), tebentafep for uveal, mRNA-4100 vaccine trials, brain mets expertise.
Explore USAChina — Mucosal/Acral & TIL Trials
Global expertise in mucosal/acral, PD-1+axitinib, KIT inhibitors, TIL trials, $20K-$60K cost.
Explore ChinaGermany — Uveal & Brain Mets
EMA approvals, adjuvant therapy, uveal + brain mets expertise (Charité/Heidelberg).
Explore GermanySouth Korea — Advanced IO & Brain MDT
JCI-accredited, advanced IO, multidisciplinary brain mets team.
Explore South KoreaIndia — Cost-Effective IO Biosimilars
Affordable IO biosimilars, TIL trials at major centers.
Explore IndiaTurkey — Regional Hub
Nivo+ipi access, Arabic/Persian support, regional hub for Middle East.
Explore TurkeyPatient Profiles: Which Path Fits You?
Five common melanoma scenarios and their recommended pathways.
Stage III, Just Diagnosed
Newly diagnosed stage III cutaneous melanoma. Sentinel node positive.
Failed PD-1, BRAF-WT
Stage IV cutaneous melanoma progressed on pembrolizumab. BRAF wild-type.
Uveal Melanoma
Stage IV uveal melanoma. Liver metastases present.
Mucosal / Acral
Stage IV mucosal melanoma. Low TMB, KIT-mutated.
Brain Metastases
Stage IV melanoma with 2 asymptomatic brain lesions.
Frequently Asked Questions
Common questions about melanoma treatment, biomarkers, and access.
Yes. Lifileucel (Amtagvi, Iovance Biotherapeutics) was FDA-approved in February 2024 for patients with unresectable or metastatic melanoma who have progressed on PD-1 therapy. It is the first TIL therapy and the first cell therapy approved for a solid tumor. Objective response rate in C-144-01 trial was ~31%, with durable responses exceeding 2 years.
Three major advances: (1) 10-year follow-up data from CheckMate-067 shows >50% overall survival at 10 years with nivolumab+ipilimumab combination. (2) Neoadjuvant NADINA trial established nivo+ipi before surgery as standard for stage III. (3) mRNA vaccine mRNA-4100 (V940) + pembrolizumab showed significant recurrence-free survival benefit in KEYNOTE-942, with Phase 3 ongoing.
For most patients, immunotherapy-first (nivo+ipi or pembrolizumab) is preferred due to durable responses and potential for cure. BRAF/MEK targeted therapy is used when rapid disease control is needed (high tumor burden, symptomatic disease, or organ dysfunction) or after immunotherapy failure.
Yes. Nivolumab+ipilimumab combination has shown intracranial response rates of 55-60% in patients with asymptomatic brain metastases. Stereotactic radiosurgery (SRS) can be added for larger or symptomatic lesions. Best managed at high-volume centers in the USA, Germany, and South Korea.
Yes. mRNA-4100 (V940, from Moderna) is a personalized neoantigen vaccine. In the KEYNOTE-942 trial, mRNA-4100 + pembrolizumab showed a significant reduction in recurrence risk compared to pembrolizumab alone in high-risk stage III/IV melanoma. Phase 3 trials are ongoing. Access is currently through clinical trial enrollment.
Subtype-driven: Cutaneous post-PD-1 progression → USA (FDA-approved TIL lifileucel) or China (TIL trials); Mucosal/acral melanoma → China (KIT inhibitors, PD-1+axitinib); Uveal melanoma → USA/Germany (tebentafep, liver-directed therapy); Budget-friendly IO → India (biosimilars) or Turkey (regional hub with Arabic/Persian support).
Related Decision Resources
China: Mucosal/Acral & TIL Trials
Global expertise in mucosal/acral melanoma, KIT inhibitors, and TIL trials.
View China Guide →TIL Therapy Deep-Dive
Complete guide to lifileucel, FDA approval, C-144-01 data, and access pathways.
Explore TIL Therapy →Clinical Trials Database
Search active melanoma trials by subtype, biomarker, and country.
Search Trials →Cost Transparency
Real-world costs for TIL, IO, BRAF/MEK, and tebentafep across 7 countries.
View Cost Guide →Ready to Match Your Melanoma to the Right Pathway?
Submit your pathology, BRAF/KIT results, and treatment history. Our oncology team analyzes your molecular profile within 48 hours — identifying the optimal TIL trial, neoadjuvant strategy, BRAF/MEK pathway, or vaccine trial.
Free • Confidential • 48-Hour Response • No Obligation • HIPAA-Aligned